Can Fite Biopharma Ltd ADR (CANF) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Can Fite Biopharma Ltd ADR stock (CANF) is currently trading at $3.13. Can Fite Biopharma Ltd ADR PS ratio (Price-to-Sales) is 12.43. Analyst consensus price target for CANF is $3.50. WallStSmart rates CANF as Sell.
- CANF PE ratio analysis and historical PE chart
- CANF PS ratio (Price-to-Sales) history and trend
- CANF intrinsic value — DCF, Graham Number, EPV models
- CANF stock price prediction 2025 2026 2027 2028 2029 2030
- CANF fair value vs current price
- CANF insider transactions and insider buying
- Is CANF undervalued or overvalued?
- Can Fite Biopharma Ltd ADR financial analysis — revenue, earnings, cash flow
- CANF Piotroski F-Score and Altman Z-Score
- CANF analyst price target and Smart Rating
Can Fite Biopharma Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Can Fite Biopharma Ltd ADR (CANF) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Can Fite Biopharma Ltd ADR (CANF) Key Strengths (1)
Trading at 1.59x book value, attractively priced
Supporting Valuation Data
Can Fite Biopharma Ltd ADR (CANF) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -36.10%, a shrinking business
Very expensive at 12.4x annual revenue
Very low institutional interest at 5.53%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Can Fite Biopharma Ltd ADR (CANF) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.59) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (12.43) suggest expensive pricing. Growth concerns include Revenue Growth at -36.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -264.10%, Operating Margin at -2425.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -264.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -36.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CANF Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CANF's Price-to-Sales ratio of 12.43x trades at a deep discount to its historical average of 72.99x (11th percentile). The current valuation is 96% below its historical high of 303.69x set in Mar 2016, and 371% above its historical low of 2.64x in Apr 2019. Over the past 12 months, the PS ratio has compressed from ~37.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Can Fite Biopharma Ltd ADR (CANF) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Can Fite Biopharma Ltd ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 560,000 with 36% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 271% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 36% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Can Fite Biopharma Ltd ADR.
Bottom Line
Can Fite Biopharma Ltd ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Can Fite Biopharma Ltd ADR(CANF)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer, liver and inflammatory diseases, COVID-19, and erectile dysfunction. The company is headquartered in Petah-Tikva, Israel.